Immune Thrombocytopenia
Immune thrombocytopenia (ITP) is a multifaceted autoimmune disorder characterized by the destruction of platelets and impaired platelet production. Our company's goal is to help pharmaceutical companies develop innovative therapies through comprehensive ITP diagnostics and therapeutic development services.
Introduction to Immune Thrombocytopenia
Immune thrombocytopenia, also known as idiopathic thrombocytopenic purpura (ITP), is an autoimmune disorder characterized by reduced platelet counts caused by increased platelet destruction and impaired platelet production. This condition arises when the immune system erroneously generates antibodies that target and eliminate platelets, leading to heightened bleeding tendencies. The pathogenesis of ITP involves multiple mechanisms that contribute to platelet destruction and hinder platelet production. Autoantibodies, primarily of the IgG class, attach to platelet surface antigens, resulting in their opsonization and subsequent removal by macrophages in the reticuloendothelial system, particularly in the spleen. Moreover, these autoantibodies may impede platelet production by interfering with the maturation and functioning of megakaryocytes.
Fig.1 Proposed mechanism of action of fostamatinib in immune thrombocytopenia (ITP). (Bussel J., et al., 2021)
Drug Discovery and Development for Immune Thrombocytopenia
Corticosteroids, such as prednisone and dexamethasone, are widely employed as the first-line treatment for ITP. Additionally, intravenous immunoglobulin (IVIg) is a pooled preparation of human immunoglobulin G (IgG) antibodies obtained from numerous healthy donors. It exerts diverse immunomodulatory effects, including the inhibition of autoantibody-mediated platelet destruction, suppression of inflammatory cytokines, and modulation of immune cell function. The therapeutic potential of monoclonal antibodies targeting specific immune cells or molecules has also been explored in ITP. For instance, rituximab, a monoclonal antibody that targets CD20 on B cells, has shown promise in depleting autoreactive B cells and reducing autoantibody production.
The therapy development of ITP aims to restore platelet counts and prevent bleeding complications. Our company is at the forefront of developing innovative drugs and therapeutic solutions to address the unmet scientific needs of the global pharmaceutical industry in the development of ITP therapies.
Our Services
At our company, we offer a comprehensive range of services to support the development of diagnostics and therapies for immune thrombocytopenia. Our expertise and state-of-the-art facilities enable us to provide tailored solutions to address the unique challenges associated with ITP. Disease models play a crucial role in preclinical research and drug development for ITP. Our company specializes in the development and characterization of robust and relevant disease models of ITP.
At our company, we specialize in the development of spontaneous mouse models for immune thrombocytopenia, such as (NZWxBXSB) F1 strain of mice, which develops lupus nephritis and myocardial infarction, accompanied by thrombocytopenia.
Spontaneous Mouse Models
One exemplary model developed by our team is the heparin-induced thrombocytopenia (HIT) mouse model. By utilizing mice expressing human platelet receptors and injecting them with a monoclonal antibody called KKO and heparin, this model successfully recapitulates the salient features of HIT observed in humans.
Drug-Induced Thrombocytopenia Models
Infectious thrombocytopenia, characterized by a decrease in platelet count due to viral or bacterial infections. At our company, we specialize in the development of infectious thrombocytopenia animal models to study the immune response and platelet dysregulation associated with these infections.
Infectious Thrombocytopenia Models
At our company, we offer specialized services in the development of platelet-induced thrombocytopenic animal models. By utilizing pregnant mice with humanized platelets and injecting them with antibodies targeting fetal platelet antigens, We can mimic the clinical scenario of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Platelet-Induced Thrombocytopenic Models
Our company specializes in developing robust and reliable cell-based models for studying immune thrombocytopenia (ITP). These models encompass various components, including immune cells, platelets, and target cells, to mimic the complex interactions occurring in vivo.
Organoids are three-dimensional structures derived from patient cells or stem cells that mimic the architecture and functionality of specific organs or tissues. Our company develops organoid models that incorporate patient-derived endothelial cells and platelets to study the underlying mechanisms of platelet-endothelial cell interactions.
With a team of skilled scientists, state-of-the-art facilities, and a commitment to excellence, our company is poised to make significant contributions to the field of immune thrombocytopenia. Along with the aforementioned services and models, we also offer tailored services and the development of disease modelsto cater to your specific requirements. If you have an interest in our services, please feel free to contact us without any hesitation.
References
- Bussel J., et al. "Immune thrombocytopenia." Expert Review of Hematology 14.11 (2021): 1013-1025.
- Zufferey A., et al. "Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP)." Journal of clinical medicine 6.2 (2017): 16.